Results 181 to 190 of about 2,108 (264)
14 100 LVAD patients across 21 studies were analyzed. Findings indicated that obese LVAD recipients had lower short‐term mortality and higher risk of infection, thrombosis and right heart failure. There was no difference in long‐term survival between obese and non‐obese patients.
Hugh Jacobs +11 more
wiley +1 more source
Effects of Disinfectant Solutions Against COVID-19 on Surface Roughness, Gloss, and Color of Removable Denture Materials. [PDF]
Mikeli A +5 more
europepmc +1 more source
Electrical Stimulation of Denervated Muscle: A Narrative Review
This review explores existing strategies for stimulating denervated muscle following lower motor neuron injury, including direct electrical stimulation of the muscle and artificial reinnervation to enable more comfortable and efficient indirect functional muscle stimulation.
Linshan Chu +3 more
wiley +1 more source
Color Stability of Three Ceramics After Thermocycling in Coffee, Black Tea, Cola, and Water: An In Vitro Study. [PDF]
Maleki D +4 more
europepmc +1 more source
Our study of 1026 LVAD implants revealed HeartWare had lower driveline infection rates than other LVAD types. In addition, severe diabetes was associated with higher risk, while older age and coronary artery disease were linked to a lower risk of driveline infections.
Anh Nguyen +6 more
wiley +1 more source
Facial skin color assessment and proposed skin shade guide for maxillofacial prosthesis using cluster analysis in a cohort of Indian adults. [PDF]
Pawar PG +5 more
europepmc +1 more source
In a randomized cross‐over trial, regional citrate anticoagulation provided superior biocompatibility over full‐dose unfractionated heparin during expanded hemodialysis with significantly lower activation of complement, granulocytes, and platelets without affecting dialysis efficiency. ABSTRACT Background Regional citrate anticoagulation (RCA) improves
Marija Malgaj Vrečko +7 more
wiley +1 more source
Hollow Complete Denture With a Speech Bulb Prosthesis: A Case Report. [PDF]
Sarmalkar SD +3 more
europepmc +1 more source
Multicenter real‐world cohort (n = 327) comparing LVADs: HeartMate 3 (HM3), HeartMate II (HMII), and HeartWare (HVAD). HM3 showed superior long‐term survival versus legacy devices, driven by fewer hemocompatibility‐related adverse events, especially pump thrombosis and ischemic stroke, while major bleeding was similar across devices.
Hamza H. H. Ben Nasir +9 more
wiley +1 more source

